Reported Earlier, Ascentage Pharma Highlights Broad Oncology Pipeline At ASCO 2026 With Six Abstracts Spanning CML, CLL, Pediatric Sarcomas And SDH-Deficient Tumors Across Three Lead Drug Candidates

Benzinga Newsdesk www.benzinga.com Positive 83.1%

Neg 0% Neu 0% Pos 83.1%

Comments

No comments yet. Be the first!